Helix BioMedix Inc. (HXBM.OB) Posts Record Revenue for Q2 2010
Helix BioMedix Inc., a biopharmaceutical company focused on bioactive peptides and related patents, today posted its financial results for the second quarter ended June 30, 2010. Helix reported record revenue of approximately $330,000 in the second quarter of 2010, up 139 percent compared to approximately $138,000 in the same period a year ago. The company attributes the increase to growth in license fees and peptide and consumer product sales. "I am pleased to report the achievement of our record quarterly revenue as a result of strong growth across our licensing and peptide sales and continued strength in sales of Helix…